28 May 2024
Annual General Meeting of Ipsen S.A. held on 28 May 2024
27 May 2022
ASCO 2022: New Cabometyx® data show encouraging results in monotherapy and in combination across different…
08 February 2024
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
18 November 2024
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in…
13 February 2023
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line…
Explore more press releases
Filter
Topics
Period
Filter by
recent search
Showing: 1 – 05 of 144 Press Releases
31 July 2025
31 July 2025
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
PARIS, FRANCE, 31 July 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-carebiopharmaceutical company, today presents its financial results for the first half of 2025.
24 July 2025
24 July 2025
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
PARIS, FRANCE, 24 July 2025 – Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one…
23 July 2025
23 July 2025
Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:
20 June 2025
20 June 2025
LinkedIn
Facebook
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
PARIS, FRANCE, 20 June 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients…
31 May 2025
31 May 2025
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
PARIS, France, 31 May 2025 – Late-breaking (LBA4175) post-hoc analysis data from the Phase III NAPOLI 3 study were presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These results found a median overall survival (mOS)…
Your dedicated contacts
-
Media Relations
-
